Cotrim Ds

# cotrim ds ## Overview - **Classification**: Antibiotic; Sulfonamide and Dihydrofolate Reductase Inhibitor combination. - **Mechanism**: Sulfamethoxazole (SMX) inhibits bacterial dihydrofolate synthesis. Trimethoprim (TMP) inhibits dihydrofolate reductase. This dual action synergistically blocks the bacterial folic acid pathway, inhibiting DNA/RNA synthesis. ## Primary Indications 1. **Uncomplicated Urinary Tract Infections (UTI)**: Treatment of susceptible infections. 2. **Acute Exacerbations of Chronic Bronchitis (AECB)**: For susceptible bacterial infections. 3. **Pneumocystis jirovecii Pneumonia (PCP)**: Treatment and prophylaxis. 4. **Shigellosis**: Treatment of _Shigella_ infections. 5. **Traveler's Diarrhea**: Prophylaxis and treatment. 6. **Nocardiosis**: Treatment of _Nocardia_ infections. ## Adult Dosing ### Standard Dosing **Uncomplicated UTI / AECB / Shigellosis** - **Dose**: **1 DS tablet (800 mg SMX / 160 mg TMP)** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: UTI: 3-10 days; AECB: 14 days; Shigellosis: 5 days **Pneumocystis jirovecii Pneumonia (PCP) - Treatment** - **Dose**: **15-20 mg/kg/day TMP** (and 75-100 mg/kg/day SMX) - **Frequency**: Divided into 3-4 doses per day - **Route**: Oral or IV - **Duration**: 14-21 days **Pneumocystis jirovecii Pneumonia (PCP) - Prophylaxis** - **Dose**: **1 DS tablet (800 mg SMX / 160 mg TMP)** - **Frequency**: Once daily, 3 times per week, or once daily 7 days a week. - **Route**: Oral ### Dose Adjustments - **Renal Impairment**: - CrCl **15-30 mL/min**: Reduce dose by 50% or extend interval to every 24 hours. - CrCl **<15 mL/min**: Not recommended, unless on dialysis (adjust post-dialysis). - **Hepatic Impairment**: Use with caution. No specific dose adjustments, but avoid in severe hepatic disease. - **Elderly Patients**: Increased risk of adverse effects (myelosuppression, hyperkalemia, renal impairment). Monitor closely. ## Pediatric Dosing *(Doses based on **Trimethoprim (TMP)** component)* ### Neonates (0-28 days) - **Contraindicated**: Due to risk of kernicterus (displacement of bilirubin from albumin). - **Special Notes**: Use only in exceptional circumstances under specialist supervision (e.g., congenital toxoplasmosis). ### Infants (1-12 months) **General Infections (e.g., UTI, OM)** - **Dose**: **8-10 mg/kg/day TMP** (40-50 mg/kg/day SMX) - **Frequency**: Divided every 12 hours - **Maximum**: Do not exceed adult dose. - **Special Notes**: Oral suspension is preferred for accurate dosing in this age group. **PCP Prophylaxis** - **Dose**: **5 mg/kg/day TMP** (25 mg/kg/day SMX) - **Frequency**: Divided every 12 hours, daily for 3 consecutive days/week. ### Children (1-12 years) **General Infections (e.g., UTI, Shigellosis)** - **Dose**: **8-10 mg/kg/day TMP** (40-50 mg/kg/day SMX) - **Frequency**: Divided every 12 hours - **Maximum**: **160 mg TMP / 800 mg SMX (1 DS tablet)** per dose. **PCP Treatment** - **Dose**: **15-20 mg/kg/day TMP** (75-100 mg/kg/day SMX) - **Frequency**: Divided every 6-8 hours - **Maximum**: Do not exceed adult PCP treatment dose. ### Adolescents (13-18 years) - **Dose**: Generally **adult dosing** applies. - **Maximum**: Follow adult maximum doses. ## Safety Information ### Contraindications - **Absolute**: - Documented **megaloblastic anemia** due to folate deficiency. - **Severe renal impairment** (CrCl < 15 mL/min) not on dialysis. - **Severe hepatic damage**. - **Hypersensitivity** to sulfamethoxazole, trimethoprim, or sulfonamides. - **Infants < 2 months of age** (risk of kernicterus). - **Porphyria**. - **Relative**: - Pregnancy (especially term) and breastfeeding (risk vs. benefit). - G6PD deficiency (risk of hemolytic anemia). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, skin rash (including photosensitivity). - **Common (1-10%)**: Diarrhea, headache, hyperkalemia, elevated transaminases. - **Serious but Rare**: - **Severe skin reactions**: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN). - **Blood dyscrasias**: Agranulocytosis, aplastic anemia, thrombocytopenia, hemolytic anemia. - **Hepatic necrosis**, cholestatic hepatitis. - **Acute kidney injury**, crystalluria. - **Anaphylaxis**. ### Key Drug Interactions - **Warfarin**: **Increased INR** and bleeding risk. Monitor INR closely; adjust warfarin dose. - **Methotrexate**: **Increased myelosuppression** and methotrexate toxicity. Avoid concurrent use or reduce methotrexate dose. - **Potassium-sparing diuretics / ACEIs / ARBs**: **Increased risk of hyperkalemia**. Monitor potassium, especially in elderly/renal impairment. - **Phenytoin**: **Increased phenytoin levels**. Monitor phenytoin levels; adjust dose if needed. - **Digoxin**: **Increased digoxin levels**. Monitor digoxin levels. - **Sulfonylureas (e.g., glipizide)**: **Increased risk of hypoglycemia**. Monitor blood glucose. ## Monitoring & Follow-up - **Before Treatment**: - Baseline **CBC with differential** (especially for long-term or high-dose). - **Renal function** (SCr, BUN, eGFR/CrCl). - **Electrolytes** (especially potassium). - **During Treatment**: - **CBC** (weekly for long-term/high-dose). - **Renal function, electrolytes** (weekly if renal impairment or co-meds affect K+). - Monitor for **skin reactions** (rash, blistering) and **signs of myelosuppression** (fever, sore throat, bruising). - **Clinical Signs**: - Rash, fever, sore throat, easy bruising/bleeding (hematologic, skin). - Jaundice, dark urine, severe abdominal pain (hepatic). - Decreased urine output, swelling (renal). ## Clinical Pearls - 💡 **Hydration is key**: Advise patients to drink plenty of fluids to help prevent crystalluria and kidney stone formation. - 💡 **Sun sensitivity**: Can cause photosensitivity. Counsel patients to use sun protection and avoid prolonged sun exposure. - 💡 **Administration**: Can be taken with food to minimize GI upset, though absorption may be slightly better on an empty stomach. - 💡 **Taste**: Oral suspension has a strong, often unpleasant taste. - 💡 **Folic acid**: Folic acid supplementation may be considered with high-dose or long-term therapy to reduce hematologic toxicity. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.